Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Galectin Therapeutics Q1 EPS $(0.19) Beats $(0.21) Estimate; The Company Had $17.8 Million Of Cash And Cash Equivalents, And Expects That It Will Require More Cash To Fund Operations After December 31, 2024

Author: Benzinga Newsdesk | May 15, 2023 08:18am
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 11.76 percent decrease over losses of $(0.17) per share from the same period last year.

Posted In: GALT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist